Pluristem's Plant Approval From The FDA Could Provide Pathway To New Drug Partners
- The FDA approved Pluristem’s 3-D PLX cell manufacturing plant, a noteworthy accomplishment as the agency is known for its insistence on high quality and precision.
- Additional partnering with pharmaceutical and biotechnology companies may be more likely with this approval, as Pluristem furthers its strategy that began with United Therapeutics and CHA Bio&Diostech.
- Pluristem is one of a few companies that can deliver a therapeutic solution to potential partners that are seeking new ways to treat a particular disease.
- Risks to owning the stock includes indifference from potential partners and early commercialization by stem cell competitors.